Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
9 pending office actions • 1 client • 9 examiners • 3 art units • 0 of 9 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
BakerHostetler - Inovio has 9 pending office actions in Biotechnology & Pharmaceuticals. The associated record reports 29,628 career applications, an 83.12% resolved allowance rate, and 3.51 average office actions per allowance.
The Inovio-linked docket represents a small active set relative to the career application record shown for the profile. The historical figures indicate that resolved matters have a measurable allowance outcome and generally involve multiple office-action exchanges. Because the career measures are not identified as Inovio-specific, practitioners should use them as broader firm context rather than as a direct client performance measure.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (22%) |
| §103 only | 3 (33%) |
| §112 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 1 (11%) |
| Multi-statute (no §101) | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZAMORY, JUSTIN L | 1 | 72.7% | +17.6% |
| HILL, MYRON G | 1 | 66.1% | +20.7% |
| FARRAR, LAUREN PENG | 1 | 78.7% | +15.6% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| FOLEY, SHANON A | 1 | 73.3% | +18.2% |
| ZOU, NIANXIANG | 1 | 64.0% | +25.0% |
| VU, QUYNH-NHU HOANG | 1 | 68.6% | +27.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | ZAMORY, JUSTIN L | — |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | HILL, MYRON G | — |
| 18300588 | Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) | ALAM, DANYAL HASSAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16804707 | VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD | VU, QUYNH-NHU HOANG | 37d overdue |
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | ZAMORY, JUSTIN L | — |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | HILL, MYRON G | — |
| 18493512 | Vacuum-Assisted Agent Delivery Devices, and Related Systems and Methods | FARRAR, LAUREN PENG | — |
| 18486708 | Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same | KINSEY WHITE, NICOLE ERIN | — |
| 18300973 | Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use | ALLEN, MICHAEL D | — |
| 18048776 | COMPOSITIONS AND METHODS FOR TREATING ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) | FOLEY, SHANON A | — |
| 17221032 | COMPOSITIONS AND METHODS FOR TREATING VULVAR DYSPLASIA | ZOU, NIANXIANG | — |
| Client (Assignee) | Pending OAs |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | 9 |
| Art Unit | Apps |
|---|---|
| 1671 | 4 |
| 3783 | 3 |
| 1672 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | Inovio Pharmaceuticals, Inc. | ZAMORY, JUSTIN L | 3783 | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | Inovio Pharmaceuticals, Inc. | HILL, MYRON G | 1671 | §101§103 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18493512 | Vacuum-Assisted Agent Delivery Devices, and Related Systems and Methods | Inovio Pharmaceuticals Inc. | FARRAR, LAUREN PENG | 3783 | §103 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18486708 | Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same | Inovio Pharmaceuticals, Inc. | KINSEY WHITE, NICOLE ERIN | 1672 | §103§112DP | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18300973 | Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use | Inovio Pharmaceuticals, Inc. | ALLEN, MICHAEL D | 1671 | §112 | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18300588 | Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) | Inovio Pharmaceuticals, Inc. | ALAM, DANYAL HASSAN | 1672 | §101§103 | Final Rejection | — | Pending | Apr 14, 2023 |
| 18048776 | COMPOSITIONS AND METHODS FOR TREATING ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) | Inovio Pharmaceuticals, Inc. | FOLEY, SHANON A | 1671 | DP | Final Rejection | — | Pending | Oct 21, 2022 |
| 17221032 | COMPOSITIONS AND METHODS FOR TREATING VULVAR DYSPLASIA | Inovio Pharmaceuticals, Inc. | ZOU, NIANXIANG | 1671 | §103 | Non-Final OA | — | Pending | Apr 02, 2021 |
| 16804707 | VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD | Inovio Pharmaceuticals, Inc. | VU, QUYNH-NHU HOANG | 3783 | §103 | Final Rejection | 37d overdue | Pending | Feb 28, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial83.1% of resolved applications prosecuted by Bakerhostetler - Inovio were allowed, across 29,628 applications in USPTO records.
3.51 office actions per allowed application on average.
9 pending office actions as of October 2026, for 1 client, before 9 examiners in 3 art units.
